GlassScriptPhysician profile
Joshua Thomas
NPI 1982264164
$2,907.61
in general payments reported to CMS, 2019-2025
32 companies · $683 in 2025
The $683 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $315 · 2023: $975 · 2024: $935 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,518 · Education: $74.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,518.30 |
| Education | $74.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $483.10 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Janssen Biotech, INC. | $412.20 | 2023-2025 | Darzalex, Tecvayli, Imbruvica |
| Genzyme Corporation | $254.64 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $192.08 | 2023-2025 | Keytruda, Welireg |
| Karyopharm Therapeutics INC. | $144.74 | 2023-2025 | Xpovio |
| Rigel Pharmaceuticals, INC. | $141.59 | 2022-2024 | Rezlidhia, Tavalisse |
| Blueprint Medicines Corporation | $137.50 | 2022-2024 | Ayvakit |
| Morphosys, US INC. | $85.23 | 2023 | Monjuvi |
| Glaxosmithkline, LLC. | $75.40 | 2025 | Blenrep, Zejula, Jemperli |
| Lilly USA, LLC | $74.59 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $73.51 | 2025 | Opdivo, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $70.04 | 2022-2025 | Lynparza |
| Seagen INC. | $65.12 | 2022-2023 | Adcetris |
| Regeneron Healthcare Solutions, INC. | $63.98 | 2024-2025 | Libtayo |
| Genmab U.S., INC. | $60.45 | 2023-2024 | Epkinly |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51.38 | 2023 | Venclexta |
| Adaptive Biotechnologies Corporation | $50.52 | 2023-2024 | Clonoseq |
| Takeda Pharmaceuticals U.S.A., INC. | $49.90 | 2022-2025 | Iclusig |
| Alnylam Pharmaceuticals INC. | $48.61 | 2025 | Givlaari |
| Sobi, INC | $43.48 | 2023-2024 | |
| Syndax Pharmaceuticals, INC. | $41.79 | 2025 | |
| Mirati Therapeutics, INC. | $39.41 | 2024 | Krazati |
| Acrotech Biopharma INC. | $36.22 | 2022-2023 | Beleodaq |
| Daiichi Sankyo INC. | $28.65 | 2024 | Vanflyta |
| Accord Healthcare, INC. | $28.21 | 2025 | |
| Pfizer INC. | $26.72 | 2025 | |
| Geron Corporation | $25.06 | 2025 | Rytelo |
| Bayer Healthcare Pharmaceuticals INC. | $24.97 | 2024 | |
| Eisai INC. | $24.52 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $19.95 | 2023 | Tazverik |
| Sanofi-Aventis U.S. LLC | $18.37 | 2023 | |
| Epizyme, INC. | $15.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.